Teva/Sanofi’s Phase IIb Data In IBD Look Competitive Vs. Merck, Roche

 
• By Joseph Haas
  
Teva logo outside building
Teva reported strong Phase IIb data for its anti-TL1A agent in IBD indications • Source: Shutterstock

More from Strategy

More from Therapy Areas